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Human papillomavirus (HPV)-associated
cervical cancer affects almost half a
million sexually active females each year
worldwide. Recently, however, clinical
trials of two HPV vaccines have
demonstrated successful results. 
The Gardasil vaccine (Merck) targets HPV
types 16 and 18, which are associated with
cervical cancer, and also HPV types 6 and 11,
which are associated with genital warts. In
the trial, 552 women aged 16–23 were
recruited from Brazil, Europe and USA, and
the study was carried out by the Ludwig
Institute for Cancer Research in Brazil. 
A total of 277 women were randomly
assigned to be given the vaccine and received
injections on the first day of the study, and
then again after two and six months. The
participants were followed up for 36 months
with regular gynaecological examinations. 
Among the women who received a
placebo, 36 contracted HPV or developed 
one of the diseases associated with the virus.
Of these 36 women, three developed genital
warts and three developed precancerous
cervical lesions. Among the women who
received the vaccine, four contracted HPV
but none developed any of the diseases
associated with the virus. 
Although HPV antibody levels fell at the
end of the study period among women who
received the experimental vaccine, antibody
levels were higher in this group than in
women naturally infected with HPV.
According to the researchers, the vaccine was
89% effective in preventing infection with the
four HPV types, and 100% effective in
preventing the diseases associated with these
types. 
Elsewhere, GlaxoSmithKline has reported
that its new vaccine Cervarix shows the
potential to prevent more than 70% of
cervical cancers in phase 2 clinical trials. 
As with the Gardasil vaccine, Cervarix targets
HPV types 16 and 18. 
Interestingly, participants in the two trials
were young (16–23 years) and some studies
have shown that most HPV-infected women
in this age group will not show any evidence
of infection for six to 12 months after
exposure and that 80% clear the infection
after 18 months. However, both companies
have now moved to phase 3 clinical trials 
and have recruited around 20,000
participants each. GlaxoSmithKline plans to
file for regulatory approval for Cervarix in
Europe in 2006, while Merck plans to apply
for US Food and Drug Administration (FDA)
approval in late 2005.
Both companies would like to make these
vaccines available to children as young as 10,
before they become sexually active. However,
it may prove difficult to convince parents of
the need to vaccinate their children against
a potential sexually transmitted disease at
this age. There is a school of thought to
suggest that the vaccine should be given to
babies, thus circumventing discussions of age
of first sexual activity, but some cultures may
view HPV vaccination as unethical and rule
it out completely. 
Although these two vaccines target HPV
types 16 and 18, which account for more
than 80% of cervical cancer-associated
infection, there are other high-grade HPVs,
such as types 31, 33 and 39, not covered 
by the vaccines. Hence, these two vaccines, 
if used, would not give protection against all
high-grade HPV types. 
Furthermore, the economic cost would
make it impossible for developing countries
to adopt these vaccines in the short-term, 
but the cost could be outweighed by the cost
of treating patients affected with cervical
cancer. Even if the vaccine is successful and
there are developments of new vaccines to
cover all HPV types, it should be remembered
that the vaccine will be of little use to those
already infected and that screening, diagnosis
and treatment will be required for decades
to come. 
Clearly, although these vaccines 
will contribute to the fight against cervical











Human papillomavirus-associated cervical cancer is a worldwide problem 
and vaccines against certain virus types are under development. Here, Pamela
Greenwell and Sanjiv Rughooputh take a brief look at the current position.
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‘Studies have shown
that 80% of young
women (16–23 years) 
clear an HPV infection
after 18 months’
Although HPV types
Although HPV types 16 and 18 account 
for more than 80% of cervical cancer-
associated infection, other high-grade 
types are not covered by the vaccines
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